Rhapsido — vemurafenib class
Named-patient access overview. Rhapsido is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Rhapsido
Rhapsido (vemurafenib class) is manufactured by TBD – verify and indicated for Oncology – confirm. It is a unverified approved by the US FDA in unverified and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Rhapsido
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Rhapsido for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Rhapsido is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Rhapsido in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Rhapsido in BahrainNamed-patient access, timeline, and regulatory notes
Rhapsido in BangladeshNamed-patient access, timeline, and regulatory notes
Rhapsido in EgyptNamed-patient access, timeline, and regulatory notes
Rhapsido in IndiaNamed-patient access, timeline, and regulatory notes
Rhapsido in LebanonNamed-patient access, timeline, and regulatory notes
Rhapsido in Sri LankaNamed-patient access, timeline, and regulatory notes
Rhapsido in TurkeyNamed-patient access, timeline, and regulatory notes
Rhapsido in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Rhapsido
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.